Prognostic significance of tumour‑infiltrating lymphocytes for oestrogen receptor‑negative breast cancer without lymph node metastasis

Kurozumi,Sasagu; Matsumoto,Hiroshi; Kurosumi,Masafumi; Inoue,Kenichi; Fujii,Takaaki; Horiguchi,Jun; Shirabe,Ken; Oyama,Tetsunari; Kuwano,Hiroyuki

doi:10.3892/ol.2019.9938

Prognostic significance of tumour‑infiltrating lymphocytes for oestrogen receptor‑negative breast cancer without lymph node metastasis

Authors:
- Sasagu Kurozumi
- Hiroshi Matsumoto
- Masafumi Kurosumi
- Kenichi Inoue
- Takaaki Fujii
- Jun Horiguchi
- Ken Shirabe
- Tetsunari Oyama
- Hiroyuki Kuwano
View Affiliations

Affiliations: Division of Breast Surgery, Saitama Cancer Center, Saitama 362‑0806, Japan, Department of Pathology, Saitama Cancer Center, Saitama 362‑0806, Japan, Division of Breast Oncology, Saitama Cancer Center, Saitama 362‑0806, Japan, Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma 371‑8511, Japan, Department of Breast Surgery, International University of Health and Welfare, Narita, Chiba 286‑8686, Japan, Department of Diagnostic Pathology, Gunma University Graduate School of Medicine, Maebashi, Gunma 371‑8511, Japan
Published online on: January 16, 2019 https://doi.org/10.3892/ol.2019.9938
Pages: 2647-2656
Copyright: © Kurozumi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumour‑infiltrating lymphocytes (TILs) are regarded as significant prognostic markers in patients with breast cancer. However, the prognostic utility of TIL expression based on the intrinsic subtypes has just been identified. The present study investigated the relationship between TIL grades and prognosis in 294 Japanese paitents with breast cancer stratified based on the intrinsic subtypes and clinicopathological characteristics. Stromal TIL status was evaluated using haematoxylin and eosin staining, and TIL grades were categorised into low (<10%), intermediate (≥10 and ≤40%) and high (>40%) groups. The relationship between TIL expression and the intrinsic subtypes, clinicopathological characteristics and patient prognosis was analyzed. It was revealed that high TIL expression was correlated with negative oestrogen receptor (ER) expression and high histological grade (P<0.001). Among the ER‑negative patients, the relapse‑free survival (RFS) rate of the high‑grade TIL group was significantly higher than that of the low‑grade TIL group (P=0.04). Among the ER‑negative patients without lymph node metastasis, RFS and cancer‑specific survival (CSS) rates of patients with high‑grade TILs were significantly higher than the RFS and CSS rates of patients with low‑grade TILs (P=0.01). However, among ER‑positive patients, RFS was significantly higher in the low‑grade TIL group than in the high‑grade TIL group (P=0.02). In conclusion, TIL expression correlated with ER status and tumour proliferation. High TIL expression was a poor prognostic marker in ER‑positive patients but was a good prognostic marker in ER‑negative patients. Therefore, the biological association between TILs and primary breast tumours may differ between ER‑positive and ER‑negative breast cancer.

View Figures

View References

1	Stanton SE, Adams S and Disis ML: Variation in incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: A systematic review. JAMA Oncol. 2:1354–1360. 2016. View Article : Google Scholar : PubMed/NCBI
2	Klein E, Becker S, Svedmyr E, Jondal M and Vánky F: Tumor infiltrating lymphocytes. Ann N Y Acad Sci. 276:207–216. 1976. View Article : Google Scholar : PubMed/NCBI
3	Galon J, Angell HK, Bedognetti D and Marincola FM: The continuum of cancer immunosurveillance: Prognostic, predictive, and mechanistic signatures. Immunity. 39:11–26. 2013. View Article : Google Scholar : PubMed/NCBI
4	Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ and Loi S: Clinical relevance of host immunity in breast cancer: From TILs to the clinic. Nat Rev Clin Oncol. 13:228–241. 2016. View Article : Google Scholar : PubMed/NCBI
5	Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Aura C, de Azambuja E, Eidtmann H, Ellis CE, Baselga J, et al: Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: A secondary analysis of the NeoALTTO Trial. JAMA Oncol. 1:448–454. 2015. View Article : Google Scholar : PubMed/NCBI
6	Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, et al: Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 28:105–113. 2010. View Article : Google Scholar : PubMed/NCBI
7	Issa-Nummer Y, Darb-Esfahani S, Loibl S, Kunz G, Nekljudova V, Schrader I, Sinn BV, Ulmer HU, Kronenwett R, Just M, et al: Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer-a substudy of the neoadjuvant GeparQuinto trial. PLoS One. 8:e797752013. View Article : Google Scholar : PubMed/NCBI
8	Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, Pfitzner BM, Salat C, Loi S, Schmitt WD, et al: Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 33:983–991. 2015. View Article : Google Scholar : PubMed/NCBI
9	West NR, Milne K, Truong PT, Macpherson N, Nelson BH and Watson PH: Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res. 13:R1262011. View Article : Google Scholar : PubMed/NCBI
10	Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, et al: The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014. Ann Oncol. 26:259–271. 2014. View Article : Google Scholar : PubMed/NCBI
11	Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, et al: American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 28:2784–2795. 2010. View Article : Google Scholar : PubMed/NCBI
12	Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 138:241–256. 2014. View Article : Google Scholar : PubMed/NCBI
13	Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, et al: Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02–98. J Clin Oncol. 31:860–867. 2013. View Article : Google Scholar : PubMed/NCBI
14	Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, et al: Prognostic value of tumor-infiltrating lymphocytes in triplenegative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 32:2959–2966. 2014. View Article : Google Scholar : PubMed/NCBI
15	Loi S, Drubay D, Adams S, Francis PA, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Piccart MJ, et al: Pooled individual patient data analysis of stromal tumor infiltrating lymphocytes in primary triple negative breast cancer treated with anthracyclinebased chemotherapy. Cancer Res. 76 (suppl):abstr S1-03. 2016. View Article : Google Scholar
16	Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, et al: Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial. Ann Oncol. 25:1544–1550. 2014. View Article : Google Scholar : PubMed/NCBI
17	Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen F, Furlanetto J, et al: Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: A pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 19:40–50. 2018. View Article : Google Scholar : PubMed/NCBI
18	Heindl A, Sestak I, Naidoo K, Cuzick J, Dowsett M and Yuan Y: Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER⁺ Breast Cancer. J Natl Cancer Inst. 110:2018. View Article : Google Scholar : PubMed/NCBI
19	Kurozumi S, Fujii T, Matsumoto H, Inoue K, Kurosumi M, Horiguchi J and Kuwano H: Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer. Med Mol Morphol. 50:185–194. 2017. View Article : Google Scholar : PubMed/NCBI
20	Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA and Kurzrock R: Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 16:2598–2608. 2017. View Article : Google Scholar : PubMed/NCBI
21	Pereira B, Chin SF, Rueda OM, Vollan HK, Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut SJ, et al: The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 7:114792016. View Article : Google Scholar : PubMed/NCBI
22	Haricharan S, Bainbridge MN, Scheet P and Brown PH: Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: An analysis of genome sequence data. Breast Cancer Res Treat. 146:211–220. 2014. View Article : Google Scholar : PubMed/NCBI
23	Svoronos N, Perales-Puchalt A, Allegrezza MJ, Rutkowski MR, Payne KK, Tesone AJ, Nguyen JM, Curiel TJ, Cadungog MG, Singhal S, et al: Tumor cell-independent estrogen signaling drives disease progression through mobilization of myeloid-derived suppressor cells. Cancer Discov. 7:72–85. 2017. View Article : Google Scholar : PubMed/NCBI
24	Montagna E, Vingiani A, Maisonneuve P, Cancello G, Contaldo F, Pruneri G and Colleoni M: Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy. Breast. 34:83–88. 2017. View Article : Google Scholar : PubMed/NCBI
25	Topalian SL, Taube JM, Anders RA and Pardoll DM: Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 16:275–287. 2016. View Article : Google Scholar : PubMed/NCBI
26	Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 373:23–34. 2015. View Article : Google Scholar : PubMed/NCBI
27	Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al: Nivolumab versus docetaxel in advanced squamous-cell nonsmall-cell lung cancer. N Engl J Med. 373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
28	Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, et al: Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial. J Clin Oncol. 33:1430–1437. 2015. View Article : Google Scholar : PubMed/NCBI
29	Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD, et al: Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 study. J Clin Oncol. 34:2460–2467. 2016. View Article : Google Scholar : PubMed/NCBI
30	Gibney GT, Weiner LM and Atkins MB: Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 17:e542–e551. 2016. View Article : Google Scholar : PubMed/NCBI
31	Zhang M, Sun H, Zhao S, Wang Y, Pu H, Wang Y and Zhang Q: Expression of PD-L1 and prognosis in breast cancer: A meta-analysis. Oncotarget. 8:31347–31354. 2017.PubMed/NCBI
32	Soliman H, Khalil F and Antonia S: PD-L1 expression is increased in a subset of basal type breast cancer cells. PLoS One. 9:e885572014. View Article : Google Scholar : PubMed/NCBI
33	Hendry S, Pang JB, Byrne DJ, Lakhani SR, Cummings MC, Campbell IG, Mann GB, Gorringe KL and Fox SB: Relationship of the breast ductal carcinoma in situ immune microenvironment with clinicopathological and genetic features. Clin Cancer Res. 23:5210–5217. 2017. View Article : Google Scholar : PubMed/NCBI
34	Tarhini AA, Zahoor H, Yearley JH, Gibson C, Rahman Z, Dubner R, Rao UN, Sander C and Kirkwood JM: Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma. J Transl Med. 13:3192015. View Article : Google Scholar : PubMed/NCBI